Subscribe to Newsletter
Discovery & Development COVID-19, Technology and Equipment

Corporate Medicine, Government X-Rays

Lighting hits the Advanced Photon Source building at the Argonne National Laboratory, just outside Chicago.

Lighting hits the Advanced Photon Source building at the Argonne National Laboratory, just outside Chicago. Photo credit: Lawrie Skinner,

In a study of over 1200 participants recently diagnosed with COVID-19, researchers found that Paxlovid – a new oral antiviral treatment from Pfizer  –  reduced the risk of hospitalization or death in high-risk adults by 89 percent. The FDA and independent monitors have since recommended Pfizer move to the next stage of regulatory application. However, the FDA is not the only branch of the US government the drug has come into contact with. Paxlovid was planned, designed, and created using the ultrabright X-rays of the Advanced Photon Source (APS), a US Department of Energy (DOE) facility at the DOE’s Argonne National Laboratory.

Should Paxlovid achieve authorization, it could be prescribed as an accessible, at-home treatment with the potential to combat multiple kinds of coronavirus. However, as wealthy countries begin placing large orders for the drug, some observers are concerned that the result will be reduced or nonexistent access to Paxlovid in the developing world.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Angus Stewart

Associate Editor of The Medicine Maker

Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine